Pharmacogenomics: Bench to bedside

被引:181
作者
Weinshilboum, R [1 ]
Wang, LW [1 ]
机构
[1] Mayo Med Sch Mayo Grad Sch, Mayo Clin Coll Med, Dept Mol Pharmacol & Exp Therapeut, Rochester, MN 55905 USA
关键词
D O I
10.1038/nrd1497
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
Pharmacogenetics is the study of the role of inheritance in inter-individual variation in drug response. Since its origins in the mid-twentieth century, a major driving force in pharmacogenetics research has been the promise of individualized drug therapy to maximize drug efficacy and minimize drug toxicity. In recent years, the convergence of advances in pharmacogenetics with rapid developments in human genomics has resulted in the evolution of pharmacogenetics into pharmacogenomics, and led to increasing enthusiasm for the 'translation' of this evolving discipline into clinical practice. Here, we briefly summarize the development of pharmacogenetics and pharmacogenomics, and then discuss the key factors that have had an influence on - and will continue to affect - the translation of pharmacogenomics from the research bench to the bedside, highlighting the challenges that need to be addressed to achieve this goal.
引用
收藏
页码:739 / 748
页数:10
相关论文
共 71 条
[31]   Pharmacogenomic data submissions to the FDA: non-clinical case studies [J].
Leighton, JK ;
DeGeorge, J ;
Jacobson-Kram, D ;
MacGregor, J ;
Mendrick, D ;
Worobec, A .
PHARMACOGENOMICS, 2004, 5 (05) :507-511
[32]   THE CLINICAL-PHARMACOLOGY OF 6-MERCAPTOPURINE [J].
LENNARD, L .
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1992, 43 (04) :329-339
[33]   PHARMACOGENETICS OF ACUTE AZATHIOPRINE TOXICITY - RELATIONSHIP TO THIOPURINE METHYLTRANSFERASE GENETIC-POLYMORPHISM [J].
LENNARD, L ;
VANLOON, JA ;
WEINSHILBOUM, RM .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1989, 46 (02) :149-154
[34]   Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib [J].
Lynch, TJ ;
Bell, DW ;
Sordella, R ;
Gurubhagavatula, S ;
Okimoto, RA ;
Brannigan, BW ;
Harris, PL ;
Haserlat, SM ;
Supko, JG ;
Haluska, FG ;
Louis, DN ;
Christiani, DC ;
Settleman, J ;
Haber, DA .
NEW ENGLAND JOURNAL OF MEDICINE, 2004, 350 (21) :2129-2139
[35]   POLYMORPHIC HYDROXYLATION OF DEBRISOQUINE IN MAN [J].
MAHGOUB, A ;
IDLE, JR ;
DRING, LG ;
LANCASTER, R ;
SMITH, RL .
LANCET, 1977, 2 (8038) :584-586
[36]   Genetic variation in bilirubin UDP-glucuronosyltransferase gene promoter and Gilbert's syndrome [J].
Monaghan, G ;
Ryan, M ;
Seddon, R ;
Hume, R ;
Burchell, B .
LANCET, 1996, 347 (9001) :578-581
[37]   POLYMORPHIC FORMATION OF MORPHINE FROM CODEINE IN POOR AND EXTENSIVE METABOLIZERS OF DEXTROMETHORPHAN - RELATIONSHIP TO THE PRESENCE OF IMMUNOIDENTIFIED CYTOCHROME-P-450IID1 [J].
MORTIMER, O ;
PERSSON, K ;
LADONA, MG ;
SPALDING, D ;
ZANGER, UM ;
MEYER, UA ;
RANE, A .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1990, 47 (01) :27-35
[38]  
Nebert Daniel W, 2003, Am J Pharmacogenomics, V3, P361, DOI 10.2165/00129785-200303060-00002
[39]   EGFR mutations in lung cancer:: Correlation with clinical response to gefitinib therapy [J].
Paez, JG ;
Jänne, PA ;
Lee, JC ;
Tracy, S ;
Greulich, H ;
Gabriel, S ;
Herman, P ;
Kaye, FJ ;
Lindeman, N ;
Boggon, TJ ;
Naoki, K ;
Sasaki, H ;
Fujii, Y ;
Eck, MJ ;
Sellers, WR ;
Johnson, BE ;
Meyerson, M .
SCIENCE, 2004, 304 (5676) :1497-1500
[40]  
PERRY HM, 1970, J LAB CLIN MED, V76